Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Sponsor
Janssen Research & Development, LLC
Study ID
NCT05503550
Status
No Longer Available

Conditions

  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex
All
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Talquetamab — DRUG
    Talquetamab will be administered subcutaneously (SC).

Study Details

The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.

Key Dates

First listed
Aug 16, 2022
Status verified
Dec 2025

Related Studies